Search Results - "JAEHDE, U"

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping by FRANK, D, JAEHDE, U, FUHR, U

“…Cytochrome P450 2D6 (CYP2D6) is one of the most important enzymes catalyzing biotransformation of xenobiotics in the human liver. This enzyme's activity shows…”
Get full text

Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™) by Hagelstein, V., Ortland, I., Wilmer, A., Mitchell, S.A., Jaehde, U.

“…The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) was developed by the US National Cancer Institute. In…”
Get full text

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) by Joerger, M., von Pawel, J., Kraff, S., Fischer, J.R., Eberhardt, W., Gauler, T.C., Mueller, L., Reinmuth, N., Reck, M., Kimmich, M., Mayer, F., Kopp, H.-G., Behringer, D.M., Ko, Y.-D., Hilger, R.A., Roessler, M., Kloft, C., Henrich, A., Moritz, B., Miller, M.C., Salamone, S.J., Jaehde, U.

“…Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing…”
Get full text

Impact of medication reconciliation and medication reviews on the incidence of preventable adverse drug reactions during hospitalization of elderly patients. A randomized controlled trial by Schmitz, K, Lenssen, R, Wied, S, Laven, A, Berning, D, Thomeczek, C, Brokmann, J, Jaehde, U, Eisert, A

“…: Of all adverse drug reactions, 35-45% are due to medication errors and would therefore be preventable. Thus, it is essential to implement effective…”
Get more information

Comprehensive pharmaceutical care to prevent drug-related readmissions of dependent-living elderly patients: a randomized controlled trial by Lenssen, R, Schmitz, K, Griesel, C, Heidenreich, A, Schulz, J B, Trautwein, C, Marx, N, Fitzner, C, Jaehde, U, Eisert, A

“…Elderly patients are vulnerable to adverse drug reactions (ADRs). Drug-related readmissions (DRRs) can be a major consequence of ADR. Therefore, this study…”
Get full text

Doripenem Treatment during Continuous Renal Replacement Therapy by Vossen, M G, Wenisch, J M, Maier-Salamon, A, Fritsch, A, Saria, K, Zuba, C, Jilch, S, Lemmerer, R, Unger, M, Jaehde, U, Jäger, W, Thalhammer, F

“…Doripenem is a broad-spectrum parenteral carbapenem with enhanced activity against Pseudomonas aeruginosa. While the initial dosing recommendation for renally…”
Get full text

92 Role of ERK nuclear translocation in cisplatin-sensitive and -resistant ovarian cancer cells by Dilruba, S, Kalayda, G.V, Jaehde, U

Get full text

Assessment of Activity Levels for CYP2D61, CYP2D62, and CYP2D641 Genes by Population Pharmacokinetics of Dextromethorphan by Abduljalil, K, Frank, D, Gaedigk, A, Klaassen, T, Tomalik‐Scharte, D, Jetter, A, Jaehde, U, Kirchheiner, J, Fuhr, U

“…The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to…”
Get full text

Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers by Lindauer, A, Di Gion, P, Kanefendt, F, Tomalik‐Scharte, D, Kinzig, M, Rodamer, M, Dodos, F, Sörgel, F, Fuhr, U, Jaehde, U

“…A pharmacokinetic/pharmacodynamic (PK/PD) study of the tyrosine kinase inhibitor sunitinib was conducted in 12 healthy volunteers using blood pressure and…”
Get full text

Checkpointinhibitoren: Dosisindividualisierung als Schlüssel zur Kostensenkung? by Kleiner, P., Jaehde, U.

“…In diesem Artikel liegt der Fokus auf Nivolumab, einem der ersten Vertreter aus der Klasse der PD-1-Rezeptor-Antagonisten („programmed cell death protein 1“),…”
Get full text

One dose to treat them all? – Therapeutisches Drug Monitoring zur Dosisoptimierung in der oralen Antitumortherapie by Teplytska, O., Klima, F., Haas, N., Kloft, C., Jaehde, U.

“…Eine genauere Möglichkeit, Tumortherapeutika individuell zu dosieren, basiert auf einem Therapeutischen Drug Monitoring (TDM; Abb. 1). Anhand der gemessenen…”
Get full text

3066 Pharmacokinetically (PK)-guided dosing of paclitaxel in combination with carboplatin in advanced non-small cell lung cancer (NSCLC) is gender dependent: Updated results of the randomized CEPAC-TDM study by Joerger, M, Von Pawel, J, Kraff, S, Fischer, J.R, Gauler, T, Mueller, L, Reinmuth, N, Reck, M, Kimmich, M, Frank, M, Kopp, H.G, Behringer, D, Ko, Y.D, Ralf, H, Roessler, M, Kloft, C, Henrich, A, Moritz, B, Jaehde, U

Get full text

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer by Diekstra, MH, Fritsch, A, Kanefendt, F, Swen, JJ, Moes, DJAR, Sörgel, F, Kinzig, M, Stelzer, C, Schindele, D, Gauler, T, Hauser, S, Houtsma, D, Roessler, M, Moritz, B, Mross, K, Bergmann, L, Oosterwijk, E, Kiemeney, LA, Guchelaar, HJ, Jaehde, U

“…The tyrosine kinase inhibitor sunitinib is used as first‐line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed‐dose regimens…”
Get full text

310 Management of adverse drug events by Jaehde, U

Get full text

Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity by Milla, Paola, Airoldi, Mario, Weber, Günther, Drescher, Anne, Jaehde, Ulrich, Cattel, Luigi

“…Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment…”
Get full text

Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters by Lanvers-Kaminsky, C., Krefeld, B., Dinnesen, A.G., Deuster, D., Seifert, E., Würthwein, G., Jaehde, U., Pieck, A.C., Boos, J.

“…Background To overcome the ototoxicity of cisplatin, single bolus infusions were replaced by repeated prolonged infusions of lower doses or by continuous…”
Get full text

Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin by Mohn, C, Häcker, H-G, Hilger, R A, Gütschow, M, Jaehde, U

“…Albeit platinum complexes are widely used in cancer chemotherapy, their cellular processing has not been completely elucidated so far. In this study the…”
Get more information

Therapietreue in der oralen Tumortherapie by Barnert, A., Jaehde, U.

“…Treten unerwünschte Arzneimittelwirkungen (UAW) auf, muss der Patient diese selbst erkennen und sich an den Arzt wenden. Zur Einnahme von Imatinib gibt es…”
Get full text

INTERPOLAR – prospektive, interventionelle Studien im Rahmen der Medizininformatik-Initiative zur Verbesserung der Arzneimitteltherapiesicherheit in der Krankenversorgung by Loeffler, Markus, Maas, Renke, Neumann, Daniel, Scherag, André

“…Zusammenfassung Medikationsanalysen durch Stationsapotheker:innen sind eine wichtige Maßnahme der Arzneimitteltherapiesicherheit (AMTS). Dabei werden…”
Get full text

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients by Pieck, A C, Drescher, A, Wiesmann, K G, Messerschmidt, J, Weber, G, Strumberg, D, Hilger, R A, Scheulen, M E, Jaehde, U

“…In this study, we investigated the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to efficacy as well as…”
Get full text